Mesothelioma Trust Funds
Mesothelioma Support Books
Free Veterans Assistance

Brigham and Womens Hospital

Contact Information

  • 75 Francis Street Boston, MA 02115
  • (617) 732-5922

Brigham and Women’s Hospital in Boston

Brigham and Women’s Hospital in Boston, Massachusetts formed an alliance with Dana Farber/Harvard Cancer Center to provide comprehensive care to cancer patients. Generally, Dana Farber handles outpatient cases and Brigham and Women’s Hospital inpatient care. The facility also has a partnership with the Harvard Medical School teaching hospital. The facility’s 3000 physicians and 2800 nurses can serve up to 777 patients at a given time. Given the experience of the staff and the partnerships, cancer patients will receive the quality care that is needed.

Thoracic and Lung Cancer is just one of 13 cancer diseases addressed at the Brigham and Women’s Hospital. They also treat Breast Cancer, Cutaneous Cancer, Endocrine Cancer, Gastrointestinal Cancer, Genitourinary Cancer, Gynecologic Cancer, Head and Neck Cancer, Hematologic Oncology, Adult Hematology, Melanoma, Neuro-Oncology, and Sarcoma.

The hospital offers pain management, infusion, radiation, surgery, psychotherapy, and other care to cancer patients. Brigham and Women’s Hospital has received honors for being one of the best hospitals for 17 consecutive years. In the 2009-2010 report, the facility ranked 10th, making the hospital one of 21 “best of the best” hospitals in the nation. In terms of cancer treatment, the hospital ranked in the top 20 best hospitals. Its partner, Dana-Farber ranked fifth on the list nationally. Brigham and Women’s Hospital received high accolades from the University Health System Consortium. The facility was one of five academic research hospitals to receive the award for safety and quality patient care. The Brigham and Women’s Hospital also ranked number 1 in gynecology, psychiatry, and kidney disease.

Dr. David Sugarbaker is the founder of the world’s largest International Mesothelioma Program (IMP). Brigham and Women’s hospital typically serves 180 of those diagnosed with the asbestos-related cancer each year. Dr. Sugarbaker’s program includes research, patient support, and clinical trials. The research is focused on finding the causes of the disease to develop more effective treatments. New developments are made every year and the prognosis of patients receiving care at Brigham and Women’s Hospital improves.

Gavin Gordon, M.D. also contributes to the research community at Brigham and Women’s Hospital. He studies normal mesothelial cells to determine how they mutate, and why certain cancerous cells are or become drug resistant. He also studies prognostic and diagnostic testing equipment. His research has received funding from the National Cancer Institute and the Cancer Research and Prevention Foundation.

Major corporations, law firms, and other philanthropic entities have donated large sums of money to support research for rare cancer disease. In 2007, $1 million was donated towards this effort to assist those afflicted with rare cancer diseases. Other large donors have included, IBM, Larry King, Inc., Covidien, Canada Dry Potomac Corp., W.L. Gore and Associates, UBS Financial Services, Inc. and Olympus Surgical and Industrial America. Housing assistance through the Thorton and Naumes House is also available. The house will only require a maintenance fee of $30 per night.

In addition to this funding, the Brigham and Women’s Hospital receives more than $400 million annually for research. The majority of this funding originates from the National Institute of Health. Past grants have funded rare cancer diseases, Women’s Initiatives, Physician’s Health Initiatives, and Nurse’s Health Initiatives.

In rare cancer diseases, receiving an accurate and timely diagnosis is one of the most important aspects in treating a disease. Brigham and Women’s Hospital have state of the art diagnostic equipment, such as Computed Tomography (CT). The equipment identifies the location and size of the tumor. Imaging tools may also function to inform oncologists of the effectiveness of cancer treatments.